Biocryst Pharmaceuticals Inc (BCRX) concluded trading on Thursday at a closing price of $8.82, with 3.65 million shares of worth about $32.23 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 11.79% during that period and on February 13, 2025 the price saw a gain of about 0.46%. Currently the company’s common shares owned by public are about 207.12M shares, out of which, 195.37M shares are available for trading.
Stock saw a price change of 1.03% in past 5 days and over the past one month there was a price change of 21.99%. Year-to-date (YTD), BCRX shares are showing a performance of 17.29% which increased to 48.24% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.03 but also hit the highest price of $9.00 during that period. The average intraday trading volume for Biocryst Pharmaceuticals Inc shares is 2.15 million. The stock is currently trading 9.00% above its 20-day simple moving average (SMA20), while that difference is up 12.91% for SMA50 and it goes to 20.86% higher than SMA200.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) currently have 207.12M outstanding shares and institutions hold larger chunk of about 82.38% of that.
The stock has a current market capitalization of $1.83B and its 3Y-monthly beta is at 1.86. It has posted earnings per share of -$0.61 in the same period. It has Quick Ratio of 2.73. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BCRX, volatility over the week remained 3.63% while standing at 4.51% over the month.
Stock’s fiscal year EPS is expected to rise by 69.57% while it is estimated to increase by 75.19% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JP Morgan on November 20, 2023 offering an Overweight rating for the stock and assigned a target price of $10 to it. Coverage by RBC Capital Mkts stated Biocryst Pharmaceuticals Inc (BCRX) stock as an Outperform in their note to investors on September 18, 2023, suggesting a price target of $10 for the stock. On August 04, 2023, Jefferies Upgrade their recommendations, while on July 13, 2023, BofA Securities Upgrade their ratings for the stock with a price target of $10. Stock get a Buy rating from Needham on February 22, 2023.
